key: cord-0706873-c0wqn54u
authors: Zelada-Ríos, Laura; Pacheco-Barrios, Kevin; Galecio-Castillo, Milagros; Yamunaqué, Cesar; Álvarez, Kelvin; Otiniano-Sifuentes, Ricardo
title: Acute disseminated encephalomyelitis and COVID-19: A systematic synthesis of worldwide cases
date: 2021-07-27
journal: J Neuroimmunol
DOI: 10.1016/j.jneuroim.2021.577674
sha: db311100cb1a952356444489358321d2c46f90db
doc_id: 706873
cord_uid: c0wqn54u

Acute disseminated encephalomyelitis (ADEM) has been reported after coronavirus disease 2019 (COVID-19). In this review, we systematically included worldwide reported cases on this association. We included 30 case reports (pediatric and adults) and explored epidemiological and clinical evidence. We described time to diagnosis, clinical, imaging, and laboratory features, response to treatment regimens, and differences regarding severity. Also, an original case report was presented. Neurologists must be alert to the occurrence of multifocal neurological symptoms with or without encephalopathy in patients recovered from COVID-19. Timely MRI studies should be performed to establish the diagnosis and to consider early corticosteroid-based treatment.

Acute disseminated encephalomyelitis (ADEM) is a monophasic, multifocal, demyelinating, autoimmune disease that affects the central nervous system (CNS). It has been described in adults and children (Pohl et al., 2016; Schwarz et al., 2001) . It usually occurs after a systemic infection, usually viral, including certain coronavirus infections (Yeh et al., 2004) . Coronavirus disease 2019 (COVID-19) is a new entity caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is known to cause respiratory complications, from mild upper respiratory symptoms to acute respiratory failure. Since the beginning of the pandemic, many neurologic complications have been reported, including ADEM (Mao et al., 2020) . However, the clinical spectrum of this association is not clear whether it constitutes an inflammatory postinfectious process. Although, previous reviews explored the occurrence of ADEM in COVID-19 cases, most of the studies included other neurological complications of COVID-19 (Bodro et al., 2021) , did not use formal evidence assessment approaches (narrative synthesis and risk of bias assessment of case reports) (Almqvist et al., 2020; Correia et al., 2020) , and did not described the clinical spectrum nor associations between severity and outcomes; thus, current synthesized evidence identified only a subgroup of the published cases and addressed tangentially this association. Therefore, we performed a systematic review focused exclusively on ADEM including worldwide reported cases to qualitatively describe and assess its relationship with and temporal relationship (i.e., in patients with ADEM); 4) patients with acute necrotizing encephalopathy or acute hemorrhagic leukoencephalitis (AHLE, Weston-Hurst syndrome), owing to their potential different prognosis and pathophysiology (Pirko et al., 2008) (i.e., different type of CNS infiltrates, lymphocytes in ADEM and neutrophils in AHLE) that suggest different disease spectrum (Neilson, 2010) . For the diagnosis of ADEM in children, we reviewed the criteria of Krupp et al.(2013) However, as COVID-19 patients may have a fever for more than 7 days, we decided to allow those cases in which fever was not the best explanation for encephalopathy.

We used the tool proposed by Murad et al. (2018) . This tool evaluates the methodological quality of case reports/series assessing 8 questions about four domains.

Since our systematic review is not focusing on cases of adverse events, we select only 6 questions for our assessment: 1) selection (a. does the patient(s) represent(s) the whole experience of the investigator (center) or is the selection method unclear to the extent that other patients with similar presentation may not have been reported?); 2) ascertainment (b. was the exposure adequately ascertained? c. was the outcome adequately ascertained?); 3) causality (d. were other alternative causes that may explain the observation ruled out? e. was follow-up long enough for outcomes to occur?); and 4) reporting (f. is the case(s) described with sufficient details to allow other investigators to replicate the research or to allow practitioners make inferences related to their own practice?). As suggested by the authors, we summed up the scores of the six-binary responses into an aggregate score (six points at maximum).

J o u r n a l P r e -p r o o f

We used EndNote X9 software to remove duplicates. Subsequently, two authors (LZR & KPB) independently selected the reports and extracted the data in Microsoft Excel 2019. In case of inconsistencies, a third author decided whether to include the article (ROS). The extracted data included: name of the first author, year of publication, sex, age, clinical presentation, COVID-19 diagnosis and severity, laboratory finding (serological and CSF), neuroimaging description, treatment, and prognosis. We describe the categorical variables using frequencies and percentages, and the numerical through medians and interquartile ranges.

A narrative approach to synthesizing the evidence was performed by two reviewers (LZR & KPB) . Narrative synthesis is an approach to systematically organize the findings from multiple studies that depends primarily on using words and text to explain and summarize the evidence. We used a four-stage process based on previous guidelines (Popay et al., 2006) : 1) developing a theory of how/why the association can be justified (pathophysiological and clinical plausibility); 2) developing a preliminary list of synthesis categories (COVID-19 features, time interval between exposure and outcome, ADEM clinical manifestations, neuroimaging and CSF features, and treatment response and prognosis data); 3) exploring the relationships between and within the included case studies; and 4) presenting the synthesis by a summary table.

We reported the findings by descriptive statistics, using mean and ranges to summarize The average quality score was 3.84 (SD=1.30, range: 1 to 5). None of the studies reached a perfect score (six points). The exposure ascertainment and long follow-up domains were the sections with more missing information. Only eight studies reported follow-up data (longest follow-up were six months). The clinical characteristics or reported outcomes (recovery after discharge) were not associated with the case report quality, the only differences were the certainty level of COVID-19 case confirmation (PCR was most frequently used in high quality reports) and the reported details of clinical features (MRI and CSF viral panel were reported in high quality reports). The complete assessment of the included studies is reported in 

Including our original case report, we identified 30 patients (pediatric=09, adults=21) diagnosed with ADEM related with COVID-19 from 18 documents Abdi et al., 2020; Assunção et al., 2020; Dominguez-Rojas et al., El Beltagi et al., 2021; Espíndola et al., 2021; Freire-Álvarez et al., 2020; Kumar et al., 2020; Langley et al., 2020; Lopes et al., 2020; McCuddy et al., 2020; Parsons et al., 2020; Paterson et al., 2020; Pilotto et al., 2021; Umapathi et al., 2020; Utukuri et al., 2020) . Only one document was reported in non-English language (Spanish). The narrative synthesis summary is presented in Table A.2. = 3/8) and 37.5% receiving human immunoglobulin alone (N = 3/8) . All cases reported follow-up data, 77.8% (N = 7/9) reported a fully favorable outcome, , and 22.2% (N = 2/9)developed a partially favorable outcome .Relapses were not reported.

In adults, we observed a male predominance (73.68 %, 14 cases) (Abdi et al., 2020; Assunção et al., 2020; El Beltagi et al., 2021; Freire-Álvarez et al., 2020; Langley et al., 2020; Lopes et al., 2020; McCuddy et al., 2020; Paterson et al., 2020; Pilotto et al., 2021; Umapathi et al., 2020; Utukuri et al., 2020) . The mean age was 49.8 years (25 to 70 years). The mean number of days since COVID-19 infection to ADEM diagnosis was 23.2 days (4 to 60 days). The comorbidity most frequently described was hypertension (Lopes et al., 2020; McCuddy et al., 2020; Umapathi et al., 2020) , followed by diabetes (Lopes et al., 2020; McCuddy et al., 2020) . Regarding the COVID-19 symptoms, 66.7 % were severe (N = 12/18) (Assunção et al., 2020; Langley et al., 2020; Lopes et al., 2020; McCuddy et al., 2020; Parsons et al., 2020; Paterson et al., 2020; Umapathi et al., 2020), 22.2 % mild (N = 4/18) (El Beltagi et al., 2021; Freire-Álvarez et al., 2020; Kumar et al., 2020) and 11.1 % asymptomatic (N = 2/18) (Abdi et al., 2020; Utukuri et al., 2020) . The COVID-19 diagnosis was made using in CSF were available from 15 patients, with only one being positive (6.7 %) (Espíndola et al., 2021) . Thirteen cases (68.42%) had moderate/severe ADEM clinical presentation.

The most frequent clinical characteristics were encephalopathy (84.2%, N = 16/19) (Abdi et al., 2020; Assunção et al., 2020; Espíndola et al., 2021; Freire-Álvarez et al., 2020; Kumar et al., 2020; Langley et al., 2020; Lopes et al., 2020; McCuddy et al., 2020; Parsons et al., 2020; Paterson et al., 2020; Pilotto et al., 2021; Umapathi et al., 2020; Utukuri et al., 2020) , pyramidal signs (motor deficits such as hemiparesis or quadriparesis, hyperreflexia, or pathological reflexes such as Babinski) (63.1%, N = 12/19) (Abdi et al., 2020; El Beltagi et al., 2021; Langley et al., 2020; Lopes et al., 2020; McCuddy et al., 2020; Parsons et al., 2020; Paterson et al., 2020; Pilotto et al., 2021; Umapathi et al., 2020) , brainstem involvement (15.7 %, N = 3/19) (Espíndola et al., 2021; Paterson et al., 2020), ataxia (15.7 Other frequent findings were brainstem lesions (45%, N = 9/20) (Abdi et al., 2020; Assunção et al., 2020; El Beltagi et al., 2021; Kumar et al., 2020; McCuddy et al., 2020; Pilotto et al., 2021; Umapathi et al., 2020) , hemorrhagic lesions (35%, N = 7/20) (Langley et al., 2020; Lopes et al., 2020; Parsons et al., 2020; Paterson et al., 2020;  territories, 100% had supratentorial involvement and 55% infratentorial involvement.

All the lesions appeared at the same evolutionary stage.

The most frequently described CSF alteration was increased protein levels, reported in 11 cases (mean protein level: 64.7mg/dL; range: 15 to 198) (El Beltagi et al., 2021; Espíndola et al., 2021; Freire-Álvarez et al., 2020; McCuddy et al., 2020; Parsons et al., 2020; Paterson et al., 2020; Pilotto et al., 2021; Umapathi et al., 2020) . Pleocytosis was reported only in five cases (El Beltagi et al., 2021; Espíndola et al., 2021; Freire-Álvarez et al., 2020; Umapathi et al., 2020; Utukuri et al., 2020) . The presence of oligoclonal bands was reported in 15 patients, 2 were positive in the CSF and 3 were positive both in the CSF and at the serum level.The serum aquaporin-4 antibody (AQP-4) and the myelin oligodendrocyte glycoprotein antibody (MOG) were tested in 7 cases and all of them with negative results (Kumar et al., 2020; Parsons et al., 2020; Paterson et al., 2020; Umapathi et al., 2020) . Seven patients received only high-dose corticosteroids (Abdi et al., 2020; Espíndola et al., 2021; Langley et al., 2020; McCuddy et al., 2020; Paterson et al., 2020; Pilotto et al., 2021) , six received corticosteroids followed by human immunoglobulin (Kumar et al., 2020; McCuddy et al., 2020; Parsons et al., 2020; Paterson et al., 2020; Utukuri et al., 2020) , one patient also received plasma exchange (Kumar et al., 2020) and two received only human immunoglobulin (Freire-Álvarez et al., 2020; Umapathi et al., 2020) .

The clinical outcome at discharge (clinical and/or radiological) was completely favorable in 5.6 % (N = 1/18) (Espíndola et al., 2021) , partially favorable in 72.2% (N =

We created the 2-by-2 tables for adults' cases. We were unable to create the tables for pediatric cases due to missing data. We found no association for COVID-19 severity and clinical outcomes at discharge (OR=6.75, 95% CI: 0.39 to 123.27; Fisher's exact pvalue = 0.24). However, we found a statistically significant association between ADEM severity and clinical outcome at discharge (OR=0.14, 95% CI: 0.25 to 0.61; Fisher's exact p-value = 0.02). Thus, a non-mild (moderate/severe) ADEM was associated with smaller odds of favorable outcome. Finally, we found no association among COVID-19 severity and ADEM severity (OR=1.33, 95% CI: 0.08 to 17.43; Fisher's exact p-value = 0.99), or treatment type and clinical outcome at discharge (OR=1.6, 95% CI: 0.06 to 106.01; Fisher's exact p-value = 0.99).

In this systematic review we summarize the worldwide ADEM cases associated with COVID-19 disease. Including our original case report, we found 30 cases (21 adults and 9 children), with predominance of adult men. Previous reviews on neurological manifestations of COVID-19 found 1 to 13 cases of ADEM (Correia et al., 2020; Maury et al., 2021) . The ADEM diagnosis was made even after asymptomatic and mild COVID-19 cases. We reported a usual clinical and neuroimaging presentation, but with more frequent moderate/severe ADEM cases ADEM is an inflammatory and demyelinating condition of acute or subacute onset. This entity can occur at any age, but is more common in children than in adults (Tenembaum et al., 2002) . However, this distribution it is different in the cases preceded by SARS-COV-2 infection since we found a predominance of adult cases (21 adult cases vs 9 J o u r n a l P r e -p r o o f Journal Pre-proof pediatric cases). This discrepancy may be due to the fact that children are generally less prone to COVID-19 infection and usually they develop an asymptomatic or mild disease (Mehta et al., 2020) . However, although at the beginning of the pandemic it was reported that children were little affected by COVID-19 (He et al., 2021) , severe cases of COVID-19 and even neurological manifestations have recently been reported (Kim et al., 2020; . It is interesting that pediatric ADEM cases reported to date represent 30% of ADEM associated with COVID-19 (Table 2) , which suggests that although it is a rare event, physicians should assess carefully neurological symptoms as part of the post-COVID-19 follow-up in children. Another point to highlight is that ADEM-like cases have been described in the context of an entity called MIS-C (Abdel- Mehra et al., 2020) reported to appear between 10 to 54 days after COVID-19 infection (Cheung et al., 2020; Coll-Vela et al., 2020; Toubiana et al., 2020; Verdoni et al., 2020; Whittaker et al., 2020) . However, these MIS-C cases that have presented ADEM-like lesions do not have a confirmatory test for COVID-19 (they only have positive IgG serology) and were not considered in this review. MIS-C has similarities with Kawasaki disease and toxic shock syndrome, which has suggested that it is an immune-mediated postinfectious complication (Coll-Vela et al., 2020) . Based on recent reports (Feldstein et al., 2020) , most of MIS-C cases had cardiac, gastrointestinal, and hematologic clinical presentation while less than 2% had associated mild to moderate neurological symptoms (headache, altered mental status, and confusion). Thus, the linked pathophysiology between MIS-C and ADEM is not clear yet, but it is plausible that both are part of a common clinical spectrum with a shared immune-mediated phenomenon.

Regarding adult ADEM cases, the average age was around 50 years, this is higher than previous reports of ADEM where the average age was between 33 to 41 years J o u r n a l P r e -p r o o f Journal Pre-proof (Ketelslegers et al., 2011; Koelman et al., 2016; Schwarz et al., 2001) . This could be explained by the higher frequency of COVID-19 cases in older people (Shahid et al., 2020) . Also, it could suggest an influence of COVID-19 severity on the development of ADEM.A larger number of severe cases occur in older adults who often have multiple comorbidities (Helms et al., 2020) , which can be associated with a defective and reactive immune system facilitating immune post-infectious condition. However, we found that ADEM can occur in patients with mild COVID-19or even in asymptomatic patients (Abdi et al., 2020; Utukuri et al., 2020) and there was not an association between severe COVID-19 and severe ADEM. Therefore, we hypothesize that the development of COVID-19 related ADEM is multifactorial, not only dependent of the degree of previous viral exposure or the intensity of the initial immune response (that determines the COVID-19 severity).

Regarding sex as biological factor for ADEM, a male predominance has been classically described in pediatric ADEM (male/female ratio 1.8:1) (Tenembaum et al., 2002) ; however, we did not find this pattern in our included pediatric cases. Regarding adults, no predominance has been described previously (Koelman et al., 2016) .

However, we found a male/female ratio of 2.8:1 in this population. This is likely due to the fact that men are more affected by COVID 19 as reported in previous studies (Grasselli et al.,2020; Peckham et al.,2020) .

Encephalopathy is a frequent manifestation of ADEM in children and being part of the diagnostic criteria. It must not explained by fever, systemic disease or post-ictal symptoms (Krupp et al., 2013) . However, we consider that in the context of COVID-19 disease it is expected to find fever, as occurred in 2 of the cases reviewed; therefore, in children with encephalopathy, history of COVID-19 exposure, and fever, ADEM should J o u r n a l P r e -p r o o f Journal Pre-proof be considered as part of the differential diagnosis. In contrast, encephalopathy occurs less frequently in adults (19 to 56% of cases) (Koelman et al., 2016; Schwarz et al., 2001) . Contradictory, in the included studies, the most common neurological presentation in adults was encephalopathy. Its presence is clinically important since it helps to identify people who are less likely to have a different disease, such as multiple sclerosis, and are more likely to be a classic ADEM (Koelman et al., 2016; Schwarz et al., 2001) . In many of these cases it was only evident after removing sedation or post extubation. Hence, as this is the most frequent manifestation, there may be a delay in the diagnosis of ADEM because cases of severe COVID-19 require sedation, mechanical ventilation, and other ICU interventions that difficult the encephalopathy assessment.

The presence of pyramidal signs is extremely important because its identification is feasible in patients with severe COVID-19 who are in the ICU (by searching Babinski's sign, osteotendinous hyperreflexia, or an asymmetric motor response). It reinforces the importance of an adequate and continuous neurological evaluation in patients who are on mechanical ventilation with a prolonged stay. Likewise, as was suggested by Lopes et al (2020), one must also be alert to identify patients who present a delayed awakening once the sedation has been withdrawn. In both cases, an MRI should be requested as it allows us to establish an earlier diagnosis.

MRI plays a key role in the diagnosis of ADEM and should be performed as soon as it is suspected. The typical findings are identified as lesions with signal hyper-intensity in FLAIR and T2 sequences, they are usually multiple, asymmetric, irregular, poorly defined, and greater than 2 cm. In general, the white matter is affected, although it may involve the deep gray matter, the brainstem, the cerebellum, and the spinal cord J o u r n a l P r e -p r o o f Journal Pre-proof (Tenembaum et al., 2007) . In our included cases, various involvement patterns were observed, predominantly a white matter compromise. Although the MRI pattern does not appear to influence prognosis, it may be useful to consider differential diagnoses (Tenembaum et al., 2002) . Brainstem involvement, for example, may suggest brainstem encephalitis or anti-MOG disease, as initially suggested in our case. Although the association between anti-MOG disease and COVID-19 is unclear Pinto et al., 2020; Sawalha et al., 2020) . Furthermore, infratentorial involvement was common in our adult ADEM cases and should be within the differential diagnosis of brainstem lesions. Another useful tool when ADEM is suspected is the study of CSF, which allows us to obtain evidence of inflammation and exclude other infectious or inflammatory causes. CSF findings in ADEM are variable, from normal results to nonspecific findings such as lymphocytic pleocytosis (15-60%) or mildly elevated proteins (25-65%) (Filippi and Rocca, 2020). This was reflected in the included cases of ADEM associated with COVID-19 and can guide the diagnosis, especially when an MRI study is not possible.

The pathogenesis of ADEM associated with COVID-19 is unknown. Although neuroinvasion is well described (Baig et al., 2020) , there is a lack of detection in CSF in most cases besides evident inflammation (pleocytosis and hyperproteinemia). This raises the possibility that the majority of ADEMs associated with COVID-19 could be the result of immune-mediated mechanisms or molecular mimicry which generates an aberrant neuro-inflammatory loop, so the virus does not need to cross the blood-brain barrier to cause damage to the CNS (Franke et al., 2020). This same mechanism has been postulated for ADEM cases associated with other causes, including other coronaviruses such as MERS-CoV (Arabi et al., 2015) . However, one case isolated SARS-CoV-2 in the CSF, which raises the differential diagnosis of encephalitis associated with COVID-J o u r n a l P r e -p r o o f Journal Pre-proof 19-associated encephalitis isolated SARS-CoV-2 in the CSF (Ellul et al., 2020; Lewis et al., 2021) . Differences exist between encephalitis associated with COVID-19 and ADEM associated with COVID-19, one of them is temporality. Unlike ADEM, neurological symptoms usually appear simultaneously with respiratory symptoms in COVID-19-associated encephalitis. Brain inflammation expressed by pleocytosis is more frequent in encephalitis associated with COVID-19 (Ellul et al., 2020) and our reported case of ADEM with SARS-CoV-2 in CSF did not present pleocytosis. Finally, there appears to be a pattern of imaging damage typical of COVID-19-associated encephalitis that differs from the pattern of lesions in ADEM (Moriguchi et al., 2020). Therefore, we do not expect to find SARS-CoV-2 in the CSF of ADEM associated with COVID-19, its presence does not rule out the diagnosis and its immune-mediated mechanism. In any case, the entire clinical, laboratory, and imaging context must be assessed.

Lindan et al., (2020) recently reported two cases that had ADEM-type presentations.

One of them tested positive for anti-MOG antibodies and the other for anti-NMDAR antibodies, both could cause neurological diseases appearing after viral infections; which, as they indicate, reinforces the theory of immune-mediated damage by COVID-19 to the CNS. Other theories indicate that the virus could be mainly attached to cells and transmitted from one cell to another through a retrograde neuronal pathway, without entering the CSF compartment (Pezzini and Padovani, 2020) or that the virus was present in the CSF at concentrations below the detection level of the test method (Filippi and Rocca, 2020).

The possibility that SARS-COV-2 infection may be involved in triggering the appearance of ADEM is supported by the fact that this exposure was identified through PCR testing in most cases, that the infection precedes ADEM development, and no other potentially responsible agents were found. Additionally, most cases carried out studies to rule out other differential diagnoses such as AQP4 positive optic neuromyelitis, MOG-IgG associated disorders, autoimmune encephalitis, infectious encephalitis, among others.

Regarding clinical outcomes at discharge, we found similar pattern that previous studies where adults have worse prognosis compared to children (Koelman et al., 2016; Schwarz et al., 2001) . We found a favorable outcome of 77.8% versus 5.6% in children and adults, respectively. Based on our included studies, the historical COVID-19 severity is not related with poor prognosis, but a moderate/severe ADEM at hospitalization is associated with a poor clinical outcome at discharge. Interestingly, we found no differences among treatment regimens (steroids alone versus combined therapies), it suggests that the use of intravenous methylprednisolone and a correct tapering protocol with oral corticosteroids are the most cost-effective treatment option.

Finally, ADEM is an evolving entity, in which long-term follow-up is often required to differentiate monophasic ADEM from a first episode of multiple sclerosis or other demyelinating diseases (Schwarz et al., 2001) . Although no relapses were reported due to the short time of COVID-19 in the world and the short follow-up time of published cases, this cannot be confirmed yet.

This study has some limitations. First, it is important to note that it is not easy to Thus, we reported a close temporal association between ADEM and COVID-19, rather that probing a causal relationship. Further studies are needed to test this hypothesis.

Third, we should recognize the limited evidence in which we based our conclusions on prognosis association and treatment regimens (non-randomized and non-controlled evidence). Due to the rarity of the disease, it is unlikely that a randomized controlled trial could be performed in this population, therefore, our current evidence summary is valuable for evidence-based diagnosis and treatment of ADEM related to COVID-19.

We summarize, for the first time, the worldwide ADEM cases associated with COVID-19. The clinical and neuroimaging presentation was similar to pre-COVID-19 reports, but with more frequent severe ADEM cases, and some demographics changes due to the influence of COVID-19 epidemiology (older adults and men). We found no association between COVID-19 severity and ADEM severity at hospitalization, suggesting an immune-mediated mechanism independent of the intensity of the initial immune response. Recovery rate was very low in adults but high in children,. We found no difference between treatment protocols in terms of clinical outcome at discharge. Thus, corticosteroid-only regimens seem to be as equally effective as combined treatments, but less expensive, which could constitute the best treatment option in low-and middleincome areas. Patients with different COVID-19 severities (even asymptomatic) could develop ADEM, hence neurologists must be alert to the occurrence of multifocal neurological symptoms associated or not with encephalopathy in patients recovered from COVID-19 disease. Timely MRI studies should be performed to establish the diagnosis and considering early corticosteroid-based treatment. Further prospective J o u r n a l P r e -p r o o f cohorts are needed to assess potential relapses and differentiate monophasic ADEM from a first episode of multiple sclerosis or other demyelinating diseases. J o u r n a l P r e -p r o o f In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. 

Seven cases (77.8%) had moderate/severe ADEM clinical presentation. The COVID-19 diagnosis was made using a PCR test or an antigen test in eight cases

The result of the PCR test for COVID-19 in CSF was reported only in two cases, both negative

Other neurological findings were pyramidal signs

cerebellar signs (22.2%) (N = 2/9

Manifestaciones Extrapulmonares COVID-19 en pediatría: reporte tres casos hospital Edgardo Rebagliati Martins -Perú

Spectrum of neuroimaging findings in COVID-19

Neurological associations of COVID-19

Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development

Multisystem Inflammatory Syndrome in U

Acute hemorrhagic demyelination in a murine model of multiple sclerosis

Acute disseminated encephalomyelitis: Updates on an inflammatory CNS syndrome

Guidance on the conduct of narrative synthesis in systematic reviews: A product from the ESRC Methods Programme

CARE guidelines for case reports: explanation and elaboration document

COVID-19-Induced Acute Bilateral Optic Neuritis

Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients

COVID-19 and Older Adults: What We Know

Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients

International Pediatric MS Study Group

Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic

Encephalopathy in COVID-19 patients; viral, parainfectious, or both? eNeurologicalSci 21

ajnr;ajnr

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-J o u r n a l P r e -p r o o f HIGHLIGHTS 1. This review summarizes the worldwide ADEM cases associated with COVID-19

Corticosteroid-only regimens seems to be equally effective than combined treatments

Timely MRI studies allow early diagnosis and corticosteroid-based treatment

LGI1(-), CASPR2(-), AQP-4 (-) MP 1g daily for 5 days (2 cycles) tapered with oral prednisone Partially favorable J o u r n a l P r e -p r o o f In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed)Specifications/Comments (e.g., if payments were made to you or to your institution)Time frame: Since the initial planning of the work 1All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) __X__None J o u r n a l P r e -p r o o f